- Thiogenesis Therapeutics Corp. (TTI) has upsized its non-brokered private placement from $4 million to $5.3 million
- The company upsized the offering as a result of strong investor demand
- Thiogenesis will issue up to 10,600,000 common shares at $0.50 per share
- The company plans to use the proceeds to complete a good lab practices (GLP) study on absorption with its lead compound TTI-0102
- Thiogenesis Therapeutics Corp. is a clinical-stage biopharmaceutical company
- Thiogenesis Therapeutics Corp. opened trading at $0.62
Thiogenesis Therapeutics Corp. (TTI) has upsized its previously-announced non-brokered private placement from $4 million to $5.3 million.
Thiogenesis will issue up to 10,600,000 common shares at $0.50 per share.
The company anticipates closing of the offering as soon as possible, subject to receipt of all necessary regulatory approvals.
All securities issued will be subject to a four-month hold period pursuant to securities laws in Canada and, where applicable, the Exchange policies.
The company plans to use the proceeds to complete a good lab practices (GLP) study on absorption with its lead compound TTI-0102, reformulation work on TTI-0102 and working capital purposes.
Thiogenesis Therapeutics Corp. is a clinical-stage biopharmaceutical company operating through its wholly-owned subsidiary based in San Diego, CA.
Thiogenesis Therapeutics Corp. opened trading at $0.62 per share.
